This paper reports the differences in absorption and distribution in plasma of free and bound salicylate, and the differences in excretion of salicylic and salicyluric acid in the urine of children with Down's syndrome and in control subjects. After oral administration of a single dose of acetylsalicylic acid (35 mg/kg) to normal children, the peak level of salicylic acid in plasma occurred in 2 h and the drug level returned to the base line at approximately 8 h; in children with Down's syndrome, the peak level of salicylic acid occurred in 4 h and the drug level returned to a base line at approximately 16 h. In children with Down's syndrome, the 24-h excretion of salicylate metabolites in the urine indicated a higher level of free salicylic acid (table I) and a lower level of salicyluric acid (tables I1 and 111) when compared with the control group. Although the concentration of salicylate is small in erythrocytes, children with Down's syndrome showed a higher level when compared with their normal counterpart (table IV) . The in vitro plasma-binding studies indicated that in comparison with normal subjects, children with Down's syndrome were less capable of binding salicylate (table V) .
Introduction
cate that alterations occur in the activity of many enzymes [2, 3, 9, 10, 18, 25-27, 34, 39, 41, 48, 501 , in Although no study has been conducted to determine the level of some plasma electrolytes [23, 461 , in the the basic pharmacology of an agent in Down's syn-ratio of plasma proteins and hard tissue proteins [l,5, drome, the available evidence suggests the presence 13, 19, 36, 40, 42, 45, 47] , and in the excretion of some of subnormal or abnormal physiological and biochem-intermediary metabolites [19-22, 33, 35, 51 , 531 in ical functions in this condition. Biochemical data indi-children with Down's syndrome. These children also demonstrate altered responses to hormones and pharmacological agents. Among the systems tested, abnormalities in response have been shown with glucose, insulin, and adrenalin tolerances [6] , and with atropine [52] . Erythrocytic triiodothyronine uptake is extremely high in the presence of normal total body iodine [28] .
The significance of these abnormalities is neither clear nor generally agreed upon; nevertheless, one might wonder to what extent the factors causing these abnormalities could also result in alteration of drugmetabolizing enzymes and drug metabolism in general.
As a model for the evaluation of drug metabolism in children with Down's syndrome, a pilot study was conducted with acetylsalicylic acid. This paper reports the results of studies of the absorption, distribution, half-life, and excretion of various metabolites of acetylsalicylic acid in these children and in control subjects.
Subjects
A group of 14 physically healthy and cytogenetically similar male and female children, between 5 and 6 years of age [54] having the karyotype of Down's syndrome with trisomy G, who were free from any medication, detectable disease, or major congenital anomalies were hospitalized on a research ward. Control subjects, matched for weight and age, were chosen from the Omaha Home for Children. In all instances human rights were safeguarded [55] .
Chemical Methods
Salicylic acid in plasma was determined using the modified method of BRODIE et al. [ 12] and was modified to use less plasma. This method is specific for salicylic acid [12] and the normal constituents of plasma do not interfere to a measurable extent in the reactions. The total salicylates and salicyluric acid in urine were converted to free salicylic acid employing the method of BEDFORD et al. [4] and concentrations were expressed as equivalents of salicylic acid. The concentration of free salicylate in erythrocytes was determined and calculated according to the method of SMITH et al. [MI.
In vitro binding of salicylate. Blood for these studies was obtained by venipuncture and the heparinized plasma was used to determine the salicylate-binding capacity. The binding procedure, the dialyzing technique, the buffer (0.14 M NaCl in 0.01 M phosphate buffer adjusted to pH 7.4 at 23"), and the method of calculation of the ultrafiltrate are those of DAVIS [17] . Quantities of sodium salicylate representing 1.0-5.0 mg/ml were added to 3 ml of plasma; the plasma was placed in cellophane dialyzing tubing [57] and was suspended in 10 ml of buffer. The dialysis was allowed to proceed for 24 h. This interval had previously been shown by DAVIS [17] to be sufficient for equilibration. The concentration of bound drug at each particular concentration of salicylate was calculated by subtracting the concentration of free salicylate (outside of the dialyzing tubes) from the concentration of bound and free (inside of the dialyzing tubes) and corrected for protein volume inside the tubes.
Materials and Methods
After a 48-h period of ward acclimatization, zero-hour fasting blood and urine samples were collected. Then, unbuffered acetylsalicylic acid (35 mg/kg) [56] , crushed and preweighed, was suspended in a small amount of water and given orally followed by 200 ml of water. Capillary blood was collected in heparinized test tubes at 15 and 30 min, and 1, 2, 3, 4, 6, and 8 h after drug administration and, in subjects with Down's syndrome, up to 12-16 h or until the agent could no longer be detected in plasma.
Studies were begun at 8:00 AM in fasting subjects and breakfast was allowed after the drawing of the 1-h blood sample. Urines were collected as voided during the 24-h period of experimentation. The pH and the volume of the urines were determined and the samples were frozen at -20' without the addition of any preservatives; they were assayed within 2-3 days. Throughout the entire 3-day study period the children were fed a balanced diet that remained similar from day to day.
Results

Free Salicylic Acid of Plasma
After administration of a single dose of 35 mg/kg, the drug was absorbed rapidly from the gastrointestinal tract since it could be detected in plasma in both groups 15 min after drug administration. The groups varied, however, in that in normal children, the peak salicylic acid level in plasma occurred at 2 h and returned to the base line at approximately 8 h whereas in children with Down's syndrome, the peak level of salicylic acid in plasma occurred at 4 h and returned to the base line at approximately 16 h (table IV) .
Urinary Metabolites
The results demonstrated that in a 24-h period children with Down's syndrome excreted 48.0% of the drug as salicylic acid compared with 30.5% excreted by the control subjects (table I) . On the other hand, they excreted 30.2 % as salicyluric acid compared with 51.0% excreted by the control subjects in 24 h (tables I1 and 111). 1 Salicyluric acid concentration is expressed as equivalent of salicylic acid. 2 Normal subjects and those exhibiting Down's syndrome were 5-6 years of age. 3 The salicyluric acid excretion was greater in the normal children at P< 0.05. 4 MeanfSEM. 
Concentration qf Salicylate in Erythrocytes
The erythrocyte membrane is freely permeable to the ultrafiltrate portion of the plasma salicylates and the drug is not bound by the protein of erythrocytes [43] . Although the concentration of salicylate in the erythrocytes was small, the children with Down's syndrome showed a higher level of salicylate, which corresponded to higher plasma levels, compared with the control group (table IV).
The In Vitro Binding of Salicylate
The results of in citro plasma binding of salicylate is shown in table V. The percentage of salicylate binding decreased as the concentration of salicylate increased. Children with Down's syndrome demonstrated a lower ability to bind salicylate compared with the control group.
Urinary pH and Volume Evaluation
There was no statistically significant difference in the mean pH value or volumes of the entire urine collection of the two groups studied for 24 h.
Discussion
Orally ingested acetylsalicylic acid is absorbed rapidly from the stomach and the upper part of the small intestine. Absorption occurs predominantly by passive diffusion of acetylsalicylic acid across gastrointestinal membranes. The concentration of nonionized drug and the pH of the mucosal surface (low pH of gastric juice enhances while high pH impedes absorption) influences absorption [15] . The absorbed acetylsalicylic acid is rapidly hydrolyzed by a plasma esterase to salicylic acid. As much as 30% of an orally administered dose of acetylsalicylic acid has been found to be present in the plasma unaltered at 30 min, with almost no detectable level at 2 h [29, 32] . At the therapeutic plasma concentration, from 60 to 80% of the salicylate in human plasma is bound to plasma proteins, especially albumin [37] . Binding takes place through free carboxyl groups and the O-phenolic group enhances the affinity for protein [45] . Aspirin itself is not bound to plasma protein [16] .
The children with Down's syndrome demonstrated lower bound (table V) and higher free salicylate (table  IV) than the control group. One explanation for this may be the presence of hypoalbuminemia [5, 19, 36, 45 , 471 that results in decreased binding of free salicylic acid. Peak levels of salicylic acid were reached in 4 h in children with Down's syndrome compared with the 2-h period necessary for attainment of peak levels in normal children. Since all children were fasted at the time of drug administration, the contents of the stomach could have no effect. The delay in absorption of salicylate could be in part related to decreased plasma protein binding in the children with Down's syndrome. The accumulation of free salicylate in the circulation could retard the esterase activity and the total acetylsalicylic acid could be temporarily higher, which in turn might reduce passive diffusion from the intestinal tract into the children's circulation.
Similarly, the delay in excretion of salicylate could also relate to decreased protein binding. Salicylate not bound to albumin might have a volume of distribution much greater than in the instances where normal binding had taken place. Thus, more salicylate would be within intracellular fluid and would not be available for either conjugation or ultrafiltration at the level of kidney, on the assumption that transport occurs via protein binding. This mechanism could contribute then to both delayed conjugation and excretion of salicylic acid. This reasoning is in keeping with studies reporting the results obtained with high [49] and low [l 11 plasma salicylate levels.
The erythrocyte membrane is freely permeable to the ultrafiltrate portion of the plasma salicylate and the drug is not bound by the protein of the erythrocytes [43] . Children with Down's syndrome demonstrated higher erythrocyte levels of salicylate that corresponded to the higher plasma level of the drug.
The major route of salicylate elimination is by metabolism to salicyluric acid. Thus, the rate of excretion of salicyluric acid closely corresponds to the rate of formation [311. Children with Down's syndrome excreted significantly less salicyluric acid with correspondingly larger amounts of free salicylic acid, compared with normal subjects (table 11). The pH of the urine affects markedly the excretion of salicylates. The kidneys excrete less salicylate when the urine is acidic and more when the urine is basic. Since the pH of the urine of both groups remained the same throughout the period of study, changes in urine pH could not have had any major influence on the excretion of free salicylic acid or the formation of salicyluric acid.
Decreased salicyluric acid formation might also be explained by a decrease in the activity of hepatic enzymes that conjugate glycine with salicylic acid to form salicyluric acid [14] . Since children with Down's syndrome have some degree of liver impairment [38] , abnormalities in drug-metabolizing enzymes would not be surprising. This is consistent with the observation made by GERSHOFP et al.
[211 that children with Down's syndrome were unable to methylate some compounds at normal rates. Oral administration of p-aminobenzoic acid increases plasma level of salicylate. It has also been shown that @-aminobenzoic acid interferes with the formation of salicyluric acid and hippuric acid. This observation suggests that the enzyme system that conjugates glycine and salicylic acid or benzoic acid may be the same [43] . To test the hypothesis of subnormality in the activity of the enzyme conjugating glycine and salicylic acid, measurement of hippuric acid after a benzoic acid load was undertaken. Preliminary observations demonstrated that subjects with Down's syndrome excreted less hippuric acid after benzoic acid loading than did normal subjects. The decreased hippuric acid formation supports the view that hepatic function is abnormal in patients with Down's syndrome.
Summary
Children with Down's syndrome exhibit increased levels of free, and decreased levels of bound salicylic acid in the plasma, increased excretion of free salicylic acid, and decreased excretion of salicyluric acid in the urine. Preliminary evidence is presented that conjugation with glycine may in part explain the observations.
